CFDA Surprises Industry With Clinical Data Self-Audit Notice
This article was originally published in PharmAsia News
Executive Summary
Drug makers have 34 days to self-audit the clinical data submitted in their clinical trial or new drug filings, and to submit an authentication report bearing legal representatives’ signatures. Those failing to do so will face unannounced inspections and may have to voluntarily withdraw their regulatory filings, the China FDA has warned.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.